File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pulmonary delivery of therapeutic siRNA

TitlePulmonary delivery of therapeutic siRNA
Authors
KeywordsAerosol
Inhalation
Lung
Non-viral
SiRNA delivery
Issue Date2012
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/addr
Citation
Advanced Drug Delivery Reviews, 2012, v. 64 n. 1, p. 1-15 How to Cite?
AbstractSmall interfering RNA (siRNA) has a huge potential for the treatment or prevention of various lung diseases. Once the RNA molecules have successfully entered the target cells, they could inhibit the expression of specific gene sequence through RNA interference (RNAi) mechanism and generate therapeutic effects. The biggest obstacle to translating siRNA therapy from the laboratories into the clinics is delivery. An ideal delivery agent should protect the siRNA from enzymatic degradation, facilitate cellular uptake and promote endosomal escape inside the cells, with negligible toxicity. Lung targeting could be achieved by systemic delivery or pulmonary delivery. The latter route of administration could potentially enhance siRNA retention in the lungs and reduce systemic toxic effects. However the presence of mucus, the mucociliary clearance actions and the high degree branching of the airways present major barriers to targeted pulmonary delivery. The delivery systems need to be designed carefully in order to maximize the siRNA deposition to the diseased area of the airways. In most of the pulmonary siRNA therapy studies in vivo, siRNA was delivered either intratracheally or intranasally. Very limited work was done on the formulation of siRNA for inhalation which is believed to be the direction for future development. This review focuses on the latest development of pulmonary delivery of siRNA for the treatment of various lung diseases. © 2011 Elsevier B.V.
Persistent Identifierhttp://hdl.handle.net/10722/135355
ISSN
2015 Impact Factor: 15.606
2015 SCImago Journal Rankings: 5.200
ISI Accession Number ID
Funding AgencyGrant Number
The University of Hong Kong
Funding Information:

The authors would like to thank The University of Hong Kong, Seed Funding Programme for financial support.

References

 

DC FieldValueLanguage
dc.contributor.authorLam, JKWen_HK
dc.contributor.authorLiang, Wen_HK
dc.contributor.authorChan, HKen_HK
dc.date.accessioned2011-07-27T01:34:01Z-
dc.date.available2011-07-27T01:34:01Z-
dc.date.issued2012en_HK
dc.identifier.citationAdvanced Drug Delivery Reviews, 2012, v. 64 n. 1, p. 1-15en_HK
dc.identifier.issn0169-409Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/135355-
dc.description.abstractSmall interfering RNA (siRNA) has a huge potential for the treatment or prevention of various lung diseases. Once the RNA molecules have successfully entered the target cells, they could inhibit the expression of specific gene sequence through RNA interference (RNAi) mechanism and generate therapeutic effects. The biggest obstacle to translating siRNA therapy from the laboratories into the clinics is delivery. An ideal delivery agent should protect the siRNA from enzymatic degradation, facilitate cellular uptake and promote endosomal escape inside the cells, with negligible toxicity. Lung targeting could be achieved by systemic delivery or pulmonary delivery. The latter route of administration could potentially enhance siRNA retention in the lungs and reduce systemic toxic effects. However the presence of mucus, the mucociliary clearance actions and the high degree branching of the airways present major barriers to targeted pulmonary delivery. The delivery systems need to be designed carefully in order to maximize the siRNA deposition to the diseased area of the airways. In most of the pulmonary siRNA therapy studies in vivo, siRNA was delivered either intratracheally or intranasally. Very limited work was done on the formulation of siRNA for inhalation which is believed to be the direction for future development. This review focuses on the latest development of pulmonary delivery of siRNA for the treatment of various lung diseases. © 2011 Elsevier B.V.en_HK
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/addren_HK
dc.relation.ispartofAdvanced Drug Delivery Reviewsen_HK
dc.subjectAerosolen_HK
dc.subjectInhalationen_HK
dc.subjectLungen_HK
dc.subjectNon-viralen_HK
dc.subjectSiRNA deliveryen_HK
dc.titlePulmonary delivery of therapeutic siRNAen_HK
dc.typeArticleen_HK
dc.identifier.emailLam, JKW: jkwlam@hku.hken_HK
dc.identifier.emailChan, HK: kimchan1@hku.hk-
dc.identifier.authorityLam, JKW=rp01346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.addr.2011.02.006en_HK
dc.identifier.pmid21356260-
dc.identifier.scopuseid_2-s2.0-84858438407en_HK
dc.identifier.hkuros188422en_US
dc.identifier.hkuros202323-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84858438407&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume64en_HK
dc.identifier.issue1en_HK
dc.identifier.spage1en_HK
dc.identifier.epage15en_HK
dc.identifier.eissn1872-8294-
dc.identifier.isiWOS:000302843300003-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridLam, JKW=8404243000en_HK
dc.identifier.scopusauthoridLiang, W=37017317100en_HK
dc.identifier.scopusauthoridChan, HK=7403402677en_HK
dc.identifier.citeulike8925863-
dc.customcontrol.immutablejt 130419-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats